| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by first author.
Page 2: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 301 | 0 | 0 | 640 1997 NATURE MEDICINE 3(1):8-8 Cimons M Thalidomide resurfaces for FDA consideration | 1 | 1 |
| 302 | 7 | 10 | 1961 2004 MEDICINA CLINICA 122(15):595-596 Cistero B; Sala M; Soler A; Garcia N Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient | 0 | 0 |
| 303 | 14 | 32 | 1975 2004 UROLOGY 63(6):1061-1065 Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma | 0 | 0 |
| 304 | 0 | 0 | 1771 2003 JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
| 305 | 44 | 140 | 1183 2001 DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 14 |
| 306 | 11 | 15 | 1549 2002 REVUE DE MEDECINE INTERNE 23(7):651-656 Claudon A; Dietemann JL; De Compte AH; Hassler P Interest of thalidomide in cutaneo-mucous and hypothalamo-hypophyseal in Langerhans cell histiocytosis. | 1 | 1 |
| 307 | 0 | 0 | 482 1995 NEUROLOGY 45(4):A168-A168 CLAVELOU P; COLAMARINO R; DINCAN M; DEFFOND D; TOURNILHAC M; SOUTEYRAND P THALIDOMIDE-RELATED NEUROPATHY - A PROSPECTIVE, CLINICAL, ELECTROMYOGRAPHIC TRIAL | 1 | 1 |
| 308 | 0 | 20 | 106 1984 ARCHIVES OF DERMATOLOGY 120(3):338-341 CLEMMENSEN OJ; OLSEN PZ; ANDERSEN KE THALIDOMIDE NEUROTOXICITY | 41 | 59 |
| 309 | 0 | 0 | 264 1989 MEDICINA CLINICA 92(15):571-571 CODINA C THALIDOMIDE 1989 | 1 | 1 |
| 310 | 1 | 3 | 1877 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Cohen LB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 311 | 0 | 1 | 361 1993 GASTROENTEROLOGY 104(4):A683-A683 COHEN LB; PEAREN S; IAZZETTA J THALIDOMIDE FOR INFLAMMATORY BOWEL-DISEASE - A PRELIMINARY-REPORT | 0 | 0 |
| 312 | 1 | 5 | 1006 2000 JOURNAL OF CLINICAL ONCOLOGY 18(19):3453-3453 Cohen MH Thalidomide in the treatment of high-grade gliomas | 1 | 3 |
| 313 | 23 | 42 | 388 1994 BONE MARROW TRANSPLANTATION 14(6):937-942 COLE CH; ROGERS PCJ; PRITCHARD S; PHILLIPS G; CHAN KW THALIDOMIDE IN THE MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN FOLLOWING BONE-MARROW TRANSPLANTATION | 25 | 30 |
| 314 | 0 | 0 | 770 1999 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
| 315 | 7 | 29 | 1523 2002 LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
| 316 | 7 | 29 | 1824 2003 SEMINARS IN ONCOLOGY 30(2):270-274 Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone | 3 | 6 |
| 317 | 0 | 0 | 901 2000 BLOOD 96(11):167A-167A Coleman M; Leonard JP; Nahum K; Michaeli J Non-myelosuppressive therapy with BLT-D (Biaxin (R), low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. | 0 | 10 |
| 318 | 37 | 44 | 1218 2001 JOINT BONE SPINE 68(6):582-587 Combe B Thalidomide: new indications? | 1 | 3 |
| 319 | 0 | 0 | 1638 2003 BLOOD 102(11):450A-451A Comenzo RL; Hassoun H; Reich L; Klimek V; Kewalramani T; Dhodapkar M; Drake L; Hedvat C; Teruya-Feldstein J; Fleisher M; Filippa DA; Nimer SD Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma. | 0 | 0 |
| 320 | 0 | 0 | 755 1999 ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 321 | 11 | 47 | 1546 2002 PHARMACOTHERAPY 22(8):1019-1028 Cool RM; Herrington JD Thalidomide for the treatment of relapsed and refractory multiple myeloma | 1 | 1 |
| 322 | 0 | 0 | 1613 2003 BLOOD 102(11):259B-259B Cooper BW; Koc ON; Lazarus HM; Laughlin MJ; Myerson HJ; Creger RJ Phase II study of fludarabine, carboplatin, topotecan, and thalidomide for patients with acute myelogenous leukemia and advanced myelodysplastic syndromes. | 0 | 0 |
| 323 | 0 | 0 | 978 2000 FASEB JOURNAL 14(8):A1512-A1512 Cornely KA; Bennett NS Thalidomide makes a comeback: A case study exercise that integrates biochemistry and organic chemistry | 0 | 0 |
| 324 | 10 | 48 | 827 1999 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 80 | 127 |
| 325 | 0 | 0 | 696 1998 EUROPEAN CYTOKINE NETWORK 9(3):367-367 Corral LG; Haslett PAJ; Ocampo C; Muller GW; Wong ML; Stirling D; Kaplan G Two distinct classes of thalidomide analogues which shape potent TNF-alpha inhibitory activity, modulate other cytokines differently | 0 | 0 |
| 326 | 29 | 79 | 751 1999 ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
| 327 | 6 | 21 | 550 1996 MOLECULAR MEDICINE 2(4):506-515 Corral LG; Muller GW; Moreira AL; Chen YX; Wu MD; Stirling D; Kaplan G Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity | 44 | 63 |
| 328 | 4 | 7 | 1460 2002 HAEMATOLOGICA 87(3):327-328 Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M Advantages of using thalidomide for the management of patients with refractory myeloma | 3 | 4 |
| 329 | 7 | 14 | 1839 2004 ANNALS OF HEMATOLOGY 83(9):588-591 Corso A; Lorenzi A; Terulla V; Airo F; Varettoni M; Mangiacavalli S; Zappasodi P; Rusconi C; Lazzarino M Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone | 0 | 0 |
| 330 | 4 | 10 | 1726 2003 HAEMATOLOGICA 88(8):958-960 Corso A; Lorenzi A; Zapposodi P; Invernizzi R; Vanelli L; Lazzarino M Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 331 | 5 | 34 | 1689 2003 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 2 | 7 |
| 332 | 0 | 0 | 676 1998 BLOOD 92(10):235B-235B Costa PT; Leaf RMLV; Morais LO; Ribeiro RA Thalidomide (TLD) and pentoxifylline (PTX) prevent the development of chronic cardiomyopathy provoked by doxorubicin (DXR) in rats without inhibiting its antitumoral effect. | 0 | 2 |
| 333 | 0 | 0 | 1380 2002 BLOOD 100(11):477B-477B Cottler-Fox M; Barlogie B; Anaissie E; Zangari M; Fassas A; Lee CK; van Rhee F; Thertulien R; Tricot G Determinants of high and low CD 34 yield after CAD as part of Total Therapy II (TT II) for newly diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL). | 0 | 0 |
| 334 | 2 | 3 | 484 1995 PRESSE MEDICALE 24(1):40-40 COUDERC LJ; MATHEZ D; LEIBOWITCH J; AUTRAN B; CAUBARRERE I PROLONGED THALIDOMIDE TREATMENT IN AN HIV-INFECTED PATIENT | 0 | 1 |
| 335 | 5 | 5 | 1960 2004 MEDICAL JOURNAL OF AUSTRALIA 180(7):366-367 Coutsouvelis J; Corallo CE Thalidomide-induced bradycardia and its management | 0 | 0 |
| 336 | 2 | 6 | 84 1983 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 7(8-9):751-751 COUZIGOU P; DOUTRE MS; HOUDEE G; RICHARDMOLARD B; FLUERY B; AMOURETTI M; BEYLOT C; BERAUD C THALIDOMIDE IN THE TREATMENT OF BEHCETS SYNDROME | 0 | 9 |
| 337 | 6 | 33 | 259 1989 JOURNAL OF AUTOIMMUNITY 2(2):197-202 CRAIN E; MCINTOSH KR; GORDON G; PESTRONK A; DRACHMAN DB THE EFFECT OF THALIDOMIDE ON EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS | 7 | 9 |
| 338 | 2 | 8 | 164 1985 LANCET 2(8450):331-331 CRAWFORD CL THALIDOMIDE AND LEPROSY | 1 | 1 |
| 339 | 2 | 8 | 302 1991 BRITISH MEDICAL JOURNAL 302(6792):1603-1604 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 6 | 7 |
| 340 | 3 | 10 | 304 1991 BRITISH MEDICAL JOURNAL 303(6809):1062-1063 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 341 | 4 | 5 | 337 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 CRAWFORD CL THALIDOMIDE NEUROPATHY | 5 | 6 |
| 342 | 20 | 85 | 379 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(4):177-192 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 8 | 11 |
| 343 | 5 | 5 | 391 1994 BRITISH MEDICAL JOURNAL 308(6941):1437-1438 CRAWFORD CL SAFETY OF THALIDOMIDE | 4 | 4 |
| 344 | 4 | 5 | 551 1996 NATURE MEDICINE 2(2):132-132 Crawford CL Thalidomide neuropathy | 1 | 1 |
| 345 | 2 | 4 | 1527 2002 MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Crawford CL Thalidomide-induced neuropathy | 1 | 1 |
| 346 | 2 | 5 | 1944 2004 LANCET 363(9424):1911-1911 Crawford CL Does thalidomide have a role in leprosy? | 0 | 0 |
| 347 | 0 | 2 | 1958 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):199-200 Crawford CL Licensing thalidomide in Australia | 0 | 0 |
| 348 | 1 | 5 | 723 1998 LANCET 351(9115):1591-1591 Critchley EMR Was the thalidomide tragedy preventable? | 0 | 0 |
| 349 | 0 | 0 | 1303 2002 ARTHRITIS AND RHEUMATISM 46(9):S290-S290 Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GRV Thalidomide in lupus: Efficacy and toxicity are not dose-dependent. | 0 | 0 |
| 350 | 0 | 0 | 1082 2001 ARTHRITIS AND RHEUMATISM 44(9):S280-S280 Cuadrado MJ; Smith E; Gordon P; Karim Y; Khamashta MA; Hughes GRV Thalidomide: Efficacy and safety in 30 patients with lupus and skin involvement. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 351 | 12 | 41 | 1869 2004 BRITISH JOURNAL OF DERMATOLOGY 151(2):458-464 Cummins DL; Gaspari AA Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation | 0 | 0 |
| 352 | 8 | 12 | 1914 2004 INTERNATIONAL JOURNAL OF DERMATOLOGY 43(9):682-684 Cunha PR; de Oliveira JR; Salles MJ; Jamora J; Bystryn JC Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy | 0 | 0 |
| 353 | 10 | 19 | 1482 2002 JOURNAL OF CLINICAL MICROBIOLOGY 40(6):2302-2304 Curley MJ; Hussein SA; Hassoun PM Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma | 0 | 0 |
| 354 | 0 | 1 | 413 1994 LANCET 343(8900):795-796 CUTLER J THALIDOMIDE REVISITED | 4 | 5 |
| 355 | 0 | 12 | 211 1987 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 413:181-187 CZEJKA MJ; KOCH HP DETERMINATION OF THALIDOMIDE AND ITS MAJOR METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 22 | 23 |
| 356 | 19 | 47 | 1274 2001 SEMINARS IN ONCOLOGY 28(6):597-601 D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma | 0 | 10 |
| 357 | 0 | 83 | 1552 2002 SOCIAL HISTORY OF MEDICINE 15(1):137-158 Daemmrich A A tale of two experts: Thalidomide and political engagement in the United States and West Germany | 0 | 0 |
| 358 | 0 | 0 | 1393 2002 BONE MARROW TRANSPLANTATION 29:S255-S256 Dagan L; Ovadia R; Taou D; Bar L The introduction of thalidomide (T) in BMT programs for patients with multiple myeloma (MM): encouraging results and a challenge for nursing team | 0 | 0 |
| 359 | 9 | 42 | 1921 2004 JOURNAL OF CLINICAL ONCOLOGY 22(13):2532-2539 Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer | 0 | 0 |
| 360 | 14 | 32 | 1736 2003 INVESTIGATIONAL NEW DRUGS 21(3):359-366 Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Dalla Costa T; Di Leone LP; Schwartsmann G Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 361 | 2 | 4 | 1146 2001 BRITISH JOURNAL OF CANCER 85:25-25 Dalgleish A; Marriott J; Czajka A; Clarke I; Dredge K; Muller G; Stirling D New thalidomide analogues; Anti-cancer, anti-angiogenic and immunostimulatory. | 0 | 0 |
| 362 | 0 | 0 | 1669 2003 BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
| 363 | 13 | 33 | 1411 2002 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 6 | 11 |
| 364 | 6 | 40 | 462 1995 HAUTARZT 46(8):553-560 DALLAFIOR S; PUGIN P; CERNY T; BETTICHER D; SAURAT JH; HAUSER C A CASE OF CUTANEOUS LANGERHANS CELL GRANULOMATOSIS SUCCESSFULLY TREATED WITH 2-CHLORODEOXYADENOSINE AND THALIDOMIDE | 4 | 9 |
| 365 | 3 | 8 | 1784 2003 LEUKEMIA 17(10):2056-2057 Dalle JH; Leblond P; Decouvelaere A; Yakoub-Agha I; Preudhomme C; Nelken B; Mazingue F Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL | 0 | 0 |
| 366 | 0 | 30 | 721 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
| 367 | 3 | 9 | 871 2000 ACTA DERMATO-VENEREOLOGICA 80(1):24-25 Daly BM; Shuster S Antipruritic action of thalidomide | 3 | 9 |
| 368 | 10 | 11 | 1783 2003 LEUKEMIA 17(9):1914-1915 Damaj G; Lefrere F; Delarue R; Varet B; Furman R; Hermine O Thalidomide therapy induces response in relapsed mantle cell lymphoma | 0 | 0 |
| 369 | 0 | 0 | 464 1995 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 36(4):S225-S225 DAMATO RJ; KENYON BM FURTHER-STUDIES EXAMINING THE EFFECTS OF THALIDOMIDE ON ANGIOGENESIS | 0 | 0 |
| 370 | 0 | 0 | 407 1994 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 35(4):1996-1996 DAMATO RJ; LOUGHMAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 371 | 8 | 29 | 424 1994 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91(9):4082-4085 DAMATO RJ; LOUGHNAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 333 | 732 |
| 372 | 0 | 0 | 612 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):4467-4467 DAmato RJ; Verheul HMW; Panigrahy D; Yuan J Combination antiangiogenic therapy with thalidomide and nonsteroidal anti-inflammatory drugs (NSAIDs) | 0 | 0 |
| 373 | 6 | 15 | 1728 2003 INTERNAL MEDICINE 42(7):550-551 Dan K Thalidomide as a targeted therapy for multiple myeloma | 0 | 0 |
| 374 | 5 | 37 | 1743 2003 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 2 | 7 |
| 375 | 25 | 61 | 378 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(2):65-76 DARCY PF; GRIFFIN JP THALIDOMIDE REVISITED | 22 | 27 |
| 376 | 3 | 9 | 587 1997 CLINICAL AND EXPERIMENTAL DERMATOLOGY 22(6):297-299 Darvay A; Basarab T; Russell-Jones R Thalidomide-induced toxic pustuloderma | 4 | 8 |
| 377 | 16 | 59 | 1047 2000 QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS 93(5):305-311 Davey PP; Ashrafian H New therapies for heart failure: is thalidomide the answer? | 6 | 9 |
| 378 | 9 | 18 | 1093 2001 BLOOD 98(1):210-216 Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 50 | 94 |
| 379 | 0 | 0 | 940 2000 BLOOD 96(11):837A-837A Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin BK; Podar K; Chauhan D; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Richardson PG; Schlossman RL; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and immunomodulatory derivatives (IMiDS) augment natural killer (NK) cell cytotoxicty in multiple myeloma (MM). | 0 | 2 |
| 380 | 10 | 48 | 1816 2003 RHEUMATIC DISEASE CLINICS OF NORTH AMERICA 29(3):481-+ Davis JC; Huang F; Maksymowych W New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 381 | 0 | 0 | 371 1993 NEW SCIENTIST 137(1862):6-6 DAYTON L THALIDOMIDE HERO FOUND GUILTY OF SCIENTIFIC FRAUD | 0 | 0 |
| 382 | 2 | 6 | 1939 2004 JOURNAL OF THE ROYAL SOCIETY OF MEDICINE 97(9):443-443 de Savary N; Lee R; Vaidya B Severe hypothyroldism after thalidomide treatment | 0 | 0 |
| 383 | 12 | 17 | 863 1999 REVUE DE MEDECINE INTERNE 20(7):567-570 de Wazieres B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients | 3 | 9 |
| 384 | 4 | 5 | 791 1999 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 17(3):393-393 de Wazieres B; Gil H; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low doses of thalidomide | 2 | 3 |
| 385 | 2 | 4 | 738 1998 PALLIATIVE MEDICINE 12(3):208-209 Deaner P Thalidomide for distressing night sweats in advanced malignant disease | 12 | 13 |
| 386 | 2 | 4 | 1045 2000 PALLIATIVE MEDICINE 14(5):429-431 Deaner PB The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report | 0 | 1 |
| 387 | 10 | 30 | 1880 2004 CARCINOGENESIS 25(10):1805-1812 DeCicco KL; Tanaka T; Andreola F; De Luca LM The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPAR gamma pathway | 0 | 0 |
| 388 | 2 | 40 | 282 1990 JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 49(6):564-581 DEIONGH RU A QUANTITATIVE ULTRASTRUCTURAL-STUDY OF MOTOR AND SENSORY LUMBOSACRAL NERVE ROOTS IN THE THALIDOMIDE-TREATED RABBIT FETUS | 3 | 3 |
| 389 | 0 | 0 | 215 1987 TERATOLOGY 36(1):A8-A9 DEIONGH RU; MCCREDIE J QUANTITATIVE NEUROPATHOLOGY OF THE PERIPHERAL-NERVES IN RABBIT THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 390 | 6 | 14 | 468 1995 JOURNAL OF LIQUID CHROMATOGRAPHY 18(2):297-309 DELON A; FAVRELIERE S; COUET W; COURTOIS PH; BOUQUET S RAPID AND SENSITIVE DETERMINATION OF THALIDOMIDE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 5 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 391 | 0 | 0 | 138 1985 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 112(1):90-90 DELSOL G; DUPRE A; VIRABEN R ROSAI-DORFMAN HISTIOCYTOSIS IN A PURE CUTANEOUS FORM - THE THERAPEUTIC USE OF THALIDOMIDE | 0 | 0 |
| 392 | 19 | 46 | 1752 2003 JOURNAL OF INVESTIGATIVE DERMATOLOGY 121(5):1060-1065 Deng L; Ding WH; Granstein RD Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells | 1 | 1 |
| 393 | 2 | 3 | 501 1996 ARCHIVES OF DERMATOLOGY 132(11):1392-1393 Dereure O; BassetSeguin N; Guilhou JJ Erosive lichen planus: Dramatic response to thalidomide | 15 | 25 |
| 394 | 6 | 43 | 1412 2002 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 15 |
| 395 | 4 | 11 | 232 1988 FUNDAMENTAL & CLINICAL PHARMACOLOGY 2(6):493-497 DESCOTES J; TEDONE R; EVREUX JC ENHANCEMENT OF ANTIBODY-RESPONSE AND DELAYED-TYPE HYPERSENSITIVITY BY THALIDOMIDE IN MICE | 3 | 3 |
| 396 | 0 | 0 | 477 1995 MOLECULAR BIOLOGY OF THE CELL 6:1195-1195 DESESSO JM; HARRIS SB; SCIALLI AR; GOERINGER GC EARLY MICROSCOPIC OBSERVATIONS OF THALIDOMIDE-INDUCED LIMB DEFECTS IN NEW-ZEALAND WHITE-RABBITS | 0 | 0 |
| 397 | 0 | 0 | 781 1999 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
| 398 | 12 | 25 | 1273 2001 SEMINARS IN ONCOLOGY 28(6):593-596 Desikan RK; Jagannath S Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions | 2 | 2 |
| 399 | 0 | 0 | 1352 2002 BLOOD 100(11):384B-384B Devabhaktuni YD; Laber DA Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma. | 0 | 0 |
| 400 | 10 | 14 | 556 1996 PEDIATRIC INFECTIOUS DISEASE JOURNAL 15(5):465-467 DeVincenzo JP; Burchet SK Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers | 5 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 401 | 8 | 13 | 1903 2004 FERTILITY AND STERILITY 82(2):460-462 Dharia SP; Steinkampf MP; Cater C Thalidomide-induced amenorrhea: case report and literature review | 0 | 0 |
| 402 | 0 | 0 | 1940 2004 JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION 11(2):275A-275A Dharia SP; Steinkampf MP; Parker CR; Grubbs CJ; Crockett S The impact of thalidomide on ovarian function. | 0 | 0 |
| 403 | 2 | 8 | 656 1998 AIDS 12(3):334-335 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M Effects of thalidomide therapy in symptomatic simian immunodeficiency virus-infected cynomolgus monkeys | 0 | 0 |
| 404 | 12 | 41 | 1013 2000 JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
| 405 | 0 | 0 | 1628 2003 BLOOD 102(11):385B-385B Di Raimondo F; Pennisi A; Buglio D; Fiumara P; Palumbo GA; Giustolisi R Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma. | 0 | 0 |
| 406 | 0 | 0 | 689 1998 CIRCULATION 98(17):247-247 Dibbs ZI; Longo T; Muller GW; Zeldis J; Sivasubramanian N; Mann DL Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes | 0 | 0 |
| 407 | 12 | 24 | 1214 2001 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 55(9):627-631 Diggle GE Thalidomide: 40 years on | 7 | 10 |
| 408 | 0 | 0 | 1109 2001 BLOOD 98(11):164A-164A Dimopoulos M; Panayiotidis P; Grigoraki V; Poziopoulos C; Xilouri I; Kiamouris C; Tassidou A; Gika D; Stefanoudaki K; Anagnostopoulos N; Anagnostou D Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. | 0 | 7 |
| 409 | 14 | 23 | 1820 2003 SEMINARS IN HEMATOLOGY 40(4):8-16 Dimopoulos MA; Anagnostopoulos A Thalidomide in relapsed/refractory multiple myeloma: Pivotal trials conducted outside the United States | 0 | 0 |
| 410 | 0 | 0 | 1608 2003 BLOOD 102(11):148A-149A Dimopoulos MA; Anagnostopoulos A; Hamilos G; Zomas A; Efstathiou E; Grigoraki V; Poziopoulos C; Gika D; Xilouri I; Zorzou MP; Anagnostopoulos N Pulsed cyclophosphamide, thalidomide and dexamethasone: Long term follow-up of an oral regimen for previously treated patients with multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 411 | 51 | 94 | 1747 2003 JOURNAL OF CLINICAL ONCOLOGY 21(23):4444-4454 Dimopoulos MA; Anagnostopoulos A; Weber D Treatment of plasma cell dyserasias with thalidomide and its derivatives | 1 | 2 |
| 412 | 0 | 0 | 1353 2002 BLOOD 100(11):384B-384B Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Anagnostopoulos N; Gika D; Margaritis D; Economopoulos T Clarithromycin, thalidomide and dexamethasone for the treatment of Waldenstrom's macroglobulinemia. | 0 | 0 |
| 413 | 6 | 25 | 1823 2003 SEMINARS IN ONCOLOGY 30(2):265-269 Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone | 3 | 5 |
| 414 | 0 | 0 | 912 2000 BLOOD 96(11):286B-286B Dimopoulos MA; Viniou N; Zomas A; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotides P Treatment of Waldenstrom's macroglobulinemia with thalidomide. | 0 | 10 |
| 415 | 5 | 13 | 1075 2001 ANNALS OF ONCOLOGY 12(7):991-995 Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N Thalidomide and dexamethasone combination for refractory multiple myeloma | 30 | 41 |
| 416 | 7 | 22 | 1223 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3596-3601 Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P Treatment of Waldenstrom's macroglobulinemia with thalidomide | 17 | 28 |
| 417 | 10 | 23 | 1414 2002 CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 2 | 2 |
| 418 | 6 | 20 | 890 2000 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 126(1):89-92 Dios PD; Sopena B; Cameselle J; Butron M; Crespo M; Ocampo A Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers | 2 | 3 |
| 419 | 0 | 0 | 1372 2002 BLOOD 100(11):398A-398A Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Fonseca R; Witzig TE; Lust JA; Greipp PR; Kyle RA; Gertz MA High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis. | 0 | 2 |
| 420 | 8 | 13 | 1571 2003 AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS 10(4):257-261 Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Witzig TE; Fonseca R; Lust JA; Greipp PR; Kyle RA; Gertz MA Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 421 | 22 | 35 | 787 1999 CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
| 422 | 4 | 26 | 1521 2002 LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
| 423 | 0 | 0 | 933 2000 BLOOD 96(11):368B-368B Dmoszynska A; Hus M; Legiec W; Walter-Croneck A; Wach M Delayed stem cell transplantation in patients with relapsed or refractory multiple myeloma using thalidomide as a preparative regimen. | 0 | 0 |
| 424 | 0 | 0 | 1357 2002 BLOOD 100(11):387B-387B Dmoszynska A; Manko J; Jawniak D; Ciepluch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Soroka-Wojtaszko M; Urbanska-Rys H; Konopka L; Hus M Toxicity of thalidomide in multiple myeloma patients (long-term observations). | 0 | 0 |
| 425 | 2 | 10 | 1261 2001 POLISH JOURNAL OF PHARMACOLOGY 53(6):709-713 Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M Influence of thalidomide on Bcl(2) expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients | 0 | 0 |
| 426 | 0 | 0 | 1118 2001 BLOOD 98(11):296B-297B Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M; Domanski D Influence of thalidomide on bcl-2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow lymphocyte subsets of multiple myeloma patients. | 0 | 0 |
| 427 | 11 | 14 | 1675 2003 BRITISH JOURNAL OF DERMATOLOGY 149(2):432-433 Dobson CM; Parslew RA Exacerbation of psoriasis by thalidomide in Behcet's syndrome | 0 | 0 |
| 428 | 0 | 0 | 80 1983 CLINICAL RESEARCH 31(5):A920-A920 DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE; MILLIKAN LE THALIDOMIDE INDUCED ALTERATION OF HUMAN PERIPHERAL-BLOOD MONOCYTE ACTIVITY | 3 | 3 |
| 429 | 0 | 0 | 1511 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:641A-641A Don BR; Vu JT; Eriksson T; Scheffler M; Kaysen GA Thalidomide is rapidly metabolized in hemodialysis patients and has a 3-fold increase in clearance during dialysis. | 0 | 0 |
| 430 | 0 | 0 | 595 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PIV89-PIV89 Donahue SR; Collins JM; Flockhart DA; Abernethy DR; Trapnell CB Thalidomide pharmacokinetics do not change with chronic administration | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 431 | 0 | 0 | 1595 2003 ARTHRITIS AND RHEUMATISM 48(9):S587-S587 Doria A; Briani C; Zara G; Rondinone R; Ermani M; Della Libera S; Ghirardello A; Zampieri S; Tedesco S Prospective study on thalidomide-induced peripheral neuropathy in SLE. | 0 | 0 |
| 432 | 0 | 1 | 1245 2001 NATURE 410(6827):411-412 Dormandy T Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 433 | 11 | 19 | 1316 2002 BJU INTERNATIONAL 89(6):591-595 Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide | 1 | 4 |
| 434 | 0 | 0 | 908 2000 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
| 435 | 0 | 0 | 1333 2002 BLOOD 100(11):162A-162A Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. | 0 | 1 |
| 436 | 8 | 20 | 1671 2003 BRITISH JOURNAL OF CANCER 88(6):822-827 Drake MJ; Robson W; Mehta P; Schofield I; Neal DE; Leung HY An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer | 4 | 10 |
| 437 | 22 | 30 | 1582 2003 ANTI-CANCER DRUGS 14(5):331-335 Dredge K; Dalgleish AG; Marriott JB Thalidomide analogs as emerging anti-cancer drugs | 3 | 8 |
| 438 | 57 | 82 | 1432 2002 CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
| 439 | 10 | 36 | 1398 2002 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 10 | 16 |
| 440 | 0 | 0 | 1721 2003 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 441 | 23 | 42 | 1495 2002 JOURNAL OF IMMUNOLOGY 168(10):4914-4919 Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | 14 | 29 |
| 442 | 8 | 27 | 1235 2001 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 298(3):1221-1226 Drenth JPH; Vonk AG; Simon A; Powell R; Van der Meer JWM Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: A randomized, double-blind, placebo-controlled trial | 1 | 7 |
| 443 | 12 | 35 | 1800 2003 MOLECULAR PHARMACOLOGY 64(2):415-420 Drucker L; Uziel O; Tohami T; Shapiro H; Radnay J; Yarkoni S; Lahav M; Lishner M Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma | 0 | 1 |
| 444 | 10 | 41 | 1971 2004 PATHOLOGY INTERNATIONAL 54(5):285-294 Du WL; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment | 0 | 0 |
| 445 | 0 | 0 | 141 1985 AUSTRALIAN PAEDIATRIC JOURNAL 21(4):295-295 DUNLOP GM; MCCREDIE J QUANTITATIVE NEUROLOGICAL CHANGES IN THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 446 | 5 | 17 | 814 1999 IMMUNOPHARMACOLOGY 43(1):59-64 Dunzendorfer S; Herold M; Wiedermann CJ Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide | 8 | 8 |
| 447 | 6 | 29 | 642 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
| 448 | 7 | 15 | 1509 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(2):S193-S195 Duong DHJ; Moxley RT; Kellman RM; Pincus SH; Gaspari AA Thalidomide therapy for cicatricial pemphigoid | 0 | 0 |
| 449 | 30 | 53 | 753 1999 ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 20 | 29 |
| 450 | 5 | 31 | 1551 2002 SEMINARS IN ONCOLOGY 29(6):34-38 Durie BGM Low-dose thalidomide in myeloma: Efficacy and biologic significance | 5 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 451 | 0 | 0 | 775 1999 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
| 452 | 0 | 0 | 1104 2001 BLOOD 98(11):163A-163A Durie BGM; Stepan DE Low dose thalidomide alone and in combination: Long term follow-up. | 0 | 6 |
| 453 | 1 | 33 | 1089 2001 BIOMEDICAL CHROMATOGRAPHY 15(3):202-206 Duval R; Leveque H; Prigent Y; Aboul-Enein HY Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases | 1 | 4 |
| 454 | 0 | 0 | 983 2000 GESUNDHEITSWESEN 62(8-9):A87-A87 Edler B; Teige B; Nippert I Study on health-related quality of life among women with developmental retardation - Case of thalidomide victims | 0 | 0 |
| 455 | 2 | 5 | 74 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 EFTHIMIOU J; SPIRO SG EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 2 | 2 |
| 456 | 0 | 0 | 1597 2003 ARTHRITIS AND RHEUMATISM 48(9):S617-S617 Efthimiou P; Rosenkranz ME; Mackenzie R; Adler R; Paget SA IVIG and thalidomide combination is an effective novel therapy for scleromyxedema. | 0 | 0 |
| 457 | 0 | 2 | 220 1988 ARCHIV DER PHARMAZIE 321(9):577-577 EGER K; BOLEWSKI J; FOLKERS G; GUTBROD O; JALALIAN M; VERSPOHL E; LUPKE NP ALPHA-PHTHALIMIDOADIPINIMIDE - SYNTHESIS, TERATOGENIC PROPERTIES AND EFFECT ON THE CENTRAL NERVOUS-SYSTEM OF A HOMO-THALIDOMIDE | 0 | 0 |
| 458 | 28 | 38 | 354 1993 BONE MARROW TRANSPLANTATION 12:S26-S28 EHNINGER G; EGER K; STUHLER A; SCHULER U THALIDOMIDE - THE NEED FOR A NEW CLINICAL-EVALUATION OF AN OLD DRUG | 7 | 8 |
| 459 | 20 | 33 | 807 1999 GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 132 |
| 460 | 5 | 19 | 661 1998 ANNALS OF INTERNAL MEDICINE 128(6):494-495 Ehrlich GE Behcet disease and the emergence of thalidomide | 4 | 19 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 461 | 0 | 0 | 966 2000 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 125:S26-S27 Eichhorn A; Kirch W Thalidomide for Behcets syndrome | 0 | 0 |
| 462 | 20 | 24 | 1487 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609 Eisen T Thalidomide in solid malignancies | 6 | 12 |
| 463 | 11 | 38 | 945 2000 BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 78 | 130 |
| 464 | 4 | 12 | 1039 2000 ONCOLOGY-NEW YORK 14(12):17-20 Eisen TG Thalidomide in solid tumors: The London experience | 11 | 15 |
| 465 | 7 | 11 | 212 1987 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 64(3):289-292 EISENBUD L; HOROWITZ I; KAY B RECURRENT APHTHOUS STOMATITIS OF THE BEHCETS TYPE - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 7 | 18 |
| 466 | 2 | 13 | 1886 2004 CLINICAL AND EXPERIMENTAL DERMATOLOGY 29(3):268-270 Eisman S; Orteu CH Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment | 0 | 0 |
| 467 | 0 | 0 | 758 1999 ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
| 468 | 0 | 0 | 1634 2003 BLOOD 102(11):443A-443A El-Sherbiny YM; Davies FE; Cook G; Johnson RJ; Cullen MJ; Sah A; Rawstron AC; Richards SJ; Morgan GJ NK cell repertoire in myeloma and the impact of thalidomide. | 0 | 0 |
| 469 | 10 | 20 | 647 1997 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 84(4):362-364 Elad S; Galili D; Garfunkel AA; Or R Thalidomide-induced perioral neuropathy | 2 | 3 |
| 470 | 8 | 18 | 1926 2004 JOURNAL OF IMMUNOTHERAPY 27(4):259-264 Elaraj DM; White DE; Steinberg SM; Haworth K; Rosenberg SA; Yang JC A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 471 | 70 | 82 | 1843 2004 ANNALS OF ONCOLOGY 15(8):1151-1160 Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA Thalidomide in cancer medicine | 0 | 0 |
| 472 | 0 | 0 | 1658 2003 BLOOD 102(11):923A-924A Elliott MA; Geyer SM; Camoriano JK; Kahanic SP; Alexander SJ; Medgyesy DC; Li CY; Tefferi A Low dose thalidomide (Td) treatment in myelofibrosis with myeloid metaplasia (MMM): An NCCTG study. | 0 | 0 |
| 473 | 0 | 0 | 1135 2001 BLOOD 98(11):627A-627A Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt R; Geyer GM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia (MMM). | 0 | 1 |
| 474 | 12 | 36 | 1400 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 13 | 23 |
| 475 | 1 | 2 | 1798 2003 MEDICAL JOURNAL OF AUSTRALIA 178(8):413-413 Elwood JM Thalidomide and cancer? | 0 | 0 |
| 476 | 8 | 14 | 275 1990 EUROPEAN SURGICAL RESEARCH 22(6):336-339 EMRE S; SUMRANI N; HONG J BENEFICIAL EFFECT OF THALIDOMIDE AND CICLOSPORIN COMBINATION IN HETEROTOPIC CARDIAC TRANSPLANTATION IN RATS | 5 | 5 |
| 477 | 0 | 0 | 986 2000 HEPATOLOGY 32(4):410A-410A Enomoto N; Ikejima K; Hirose M; Ishikawa M; Konno A; Matsuyama S; Shimizu H; Kitamura T; Takei Y; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of TNF-A production by Kupffer cells. | 0 | 0 |
| 478 | 12 | 38 | 1456 2002 GASTROENTEROLOGY 123(1):291-300 Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production | 3 | 14 |
| 479 | 7 | 31 | 1561 2003 ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 27(8):2S-6S Enomoto N; Takei Y; Hirose M; Kitamura T; Ikejima K; Sato N Protective effect of thalidomide on endotoxin-induced liver injury | 0 | 1 |
| 480 | 10 | 33 | 1881 2004 CELL BIOLOGY INTERNATIONAL 28(3):237-242 Ergun MA; Konac E; Erbas D; Ekmekci A Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 481 | 5 | 5 | 590 1997 CLINICAL CHEMISTRY 43(6):1094-1095 Eriksson T; Bjorkman S Handling of blood samples for determination of thalidomide | 6 | 6 |
| 482 | 3 | 9 | 324 1992 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 582(1-2):211-216 ERIKSSON T; BJORKMAN S; FYGE A; EKBERG H DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION | 44 | 44 |
| 483 | 59 | 87 | 1188 2001 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
| 484 | 16 | 27 | 715 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 24 | 25 |
| 485 | 14 | 25 | 445 1995 CHIRALITY 7(1):44-52 ERIKSSON T; BJORKMAN S; ROTH B; FYGE A; HOGLUND P STEREOSPECIFIC DETERMINATION, CHIRAL INVERSION IN-VITRO AND PHARMACOKINETICS IN HUMANS OF THE ENANTIOMERS OF THALIDOMIDE | 57 | 80 |
| 486 | 10 | 23 | 688 1998 CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
| 487 | 27 | 36 | 1014 2000 JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
| 488 | 13 | 23 | 1761 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
| 489 | 3 | 6 | 340 1992 TRANSPLANTATION PROCEEDINGS 24(6):2560-2561 ERIKSSON T; RIESBECK K; OSTRAAT O; EKBERG H; BJORKMAN S DRUG EXPOSURE AND FLOW-CYTOMETRY ANALYSES IN A THALIDOMIDE TREATMENT SCHEDULE THAT PROLONGS RAT CARDIAC GRAFT-SURVIVAL | 6 | 7 |
| 490 | 7 | 12 | 875 2000 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 57(17):1607-1610 Eriksson T; Wallin R; Hoglund P; Roth B; Qi ZQ; Ostraat O; Bjorkman S Low bioavailability of rectally administered thalidomide | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 491 | 6 | 28 | 1294 2002 ANNALS OF ONCOLOGY 13(7):1029-1035 Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A Phase II trial of thalidomide in renal-cell carcinoma | 12 | 23 |
| 492 | 1 | 3 | 1293 2002 ANNALS OF INTERNAL MEDICINE 136(9):711-711 Escudier B; Lassau N; Leborgne S; Angevin E; Laplanche A Thalidomide and venous thrombosis | 6 | 9 |
| 493 | 3 | 7 | 1070 2001 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(2):148-149 Esteve E; Legac E Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide | 4 | 4 |
| 494 | 0 | 0 | 926 2000 BLOOD 96(11):323A-323A Estey E; Albitar M; Cortes J; Giles F; Thomas D; Koller C; Beran M; Kantarjian H Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. | 0 | 13 |
| 495 | 11 | 12 | 1071 2001 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(5):611-613 Estines O; Revuz J; Wolkenstein P; Bressieux JM; Roujeau JC; Cosnes A Sarcoidosis: thalidomide treatment in ten patients | 5 | 6 |
| 496 | 9 | 9 | 1407 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1303-1305 Eter N; Spitznas M DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture | 0 | 0 |
| 497 | 0 | 0 | 241 1988 NATURE 336(6195):101-101 EWING T THALIDOMIDE SCIENTIST GUILTY OF FRAUD SAYS COMMITTEE | 0 | 2 |
| 498 | 0 | 0 | 1243 2001 MOLECULAR BIOLOGY OF THE CELL 12:23A-23A Ezell TN Apoptotic cell death induced by low doses of the tumor necrosis alpha inhibitor, thalidomide in human T leukemic cells | 0 | 0 |
| 499 | 4 | 39 | 1694 2003 CELLULAR AND MOLECULAR BIOLOGY 49(7):1117-1124 Ezell TN; Maloney N; Githua JW; Taylor LD Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells | 0 | 0 |
| 500 | 0 | 0 | 1026 2000 MOLECULAR BIOLOGY OF THE CELL 11:452A-452A Ezell TN; Odoms S; Davis M; Taylor L Human T leukemic cells exhibit biochemical changes consistent with apoptosis after treatment with tumor necrosis factor alpha and thalidomide. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 501 | 0 | 0 | 1115 2001 BLOOD 98(11):271B-271B Fabbri A; Biscardi M; Innocenti F; Balestri F; Gavazzi S; Bellesi G; Grossi A Thalidomide in combination with amifostine in the treatment of MDS: Evaluation of clinical and laboratory findings. | 0 | 0 |
| 502 | 10 | 18 | 1233 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(2):178-181 Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results | 10 | 17 |
| 503 | 15 | 16 | 1834 2004 AMERICAN JOURNAL OF CARDIOLOGY 93(8):1052-1055 Fahdi IE; Gaddam V; Saucedo JF; Kishan CV; Vyas K; Deneke MG; Razek H; Thorn B; Bissett JK; Anaisse E; Barlogie B; Mehta JL Bradycardia during therapy for multiple myeloma with thalidomide | 0 | 0 |
| 504 | 4 | 5 | 1871 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(1):96-97 Fakhouri F; Guerraoui H; Presne C; Peltier J; Delarue R; Muret P; Knebelmann B Thalidomide in patients with multiple myeloma and renal failure | 0 | 0 |
| 505 | 73 | 144 | 1720 2003 EXPERT OPINION ON INVESTIGATIONAL DRUGS 12(7):1211-1225 Fanelli M; Sarmiento R; Gattuso D; Carillio G; Capaccetti B; Vacca A; Roccaro AM; Gasparini G Thalidomide: a new anticancer drug? | 3 | 7 |
| 506 | 16 | 33 | 1837 2004 AMERICAN JOURNAL OF VETERINARY RESEARCH 65(5):659-664 Farese JR; Fox LE; Detrisac CJ; Van Gilder JA; Roberts SL; Baldwin JA Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice | 0 | 0 |
| 507 | 0 | 0 | 1264 2001 RADIOLOGY 221:387-387 Faria SC; Charnsangavej C; Sawaf Y; Hess KR; Tamm EP; Lee T CT quantification of antiangiogenic effects of thalidomide | 0 | 0 |
| 508 | 0 | 18 | 23 1981 PATHOLOGIE BIOLOGIE 29(10):601-604 FAURE M; LEJEUNE JP; GAUCHERAND M; THIVOLET J PMN LEUKOCYTES CHEMOTAXIS - INHIBITION BY THALIDOMIDE | 6 | 9 |
| 509 | 0 | 8 | 2 1980 ARCHIVES OF DERMATOLOGICAL RESEARCH 269(3):275-280 FAURE M; THIVOLET J; GAUCHERAND M INHIBITION OF PMN LEUKOCYTES CHEMOTAXIS BY THALIDOMIDE | 59 | 70 |
| 510 | 0 | 0 | 1354 2002 BLOOD 100(11):384B-384B Fawaz A; Magro L; Leleu X; Depil S; Guillerm G; Corm S; Bauters F; Facon T; Yakoub-Agha I Impact of thalidomide on survival of patients with multiple myeloma. | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 511 | 7 | 16 | 1022 2000 MAYO CLINIC PROCEEDINGS 75(8):842-844 Federman GL; Federman DG Recalcitrant pyoderma gangrenosum treated with thalidomide | 5 | 13 |
| 512 | 0 | 0 | 488 1996 AIDS 10:P60-P60 FeregrinoGoyos M; GomezCaro WH; AlvaradoDiez R; Yieyra MPM; TorrasGiner V Thalidomide and ketoprofen reduce the incidence of adverse events of interleukin 2 and enhance the antiviral activity of CD8 in HIV/AIDS patients. | 0 | 0 |
| 513 | 20 | 52 | 456 1995 EXPERIMENTAL HEMATOLOGY 23(9):978-985 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION | 21 | 21 |
| 514 | 1 | 1 | 457 1995 EXPERIMENTAL HEMATOLOGY 23(12):1324-1324 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION (VOL 23, PG 978, 1995) | 1 | 1 |
| 515 | 14 | 63 | 1181 2001 DRUG DEVELOPMENT RESEARCH 54(4):209-218 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat | 2 | 3 |
| 516 | 17 | 47 | 1850 2004 BIOCHEMICAL PHARMACOLOGY 68(7):1321-1329 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat | 0 | 0 |
| 517 | 1 | 8 | 597 1997 DERMATOLOGY 195(4):359-361 Ferrandiz C; Carrascosa JM; Just M; Bielsa I; Ribera M Sequential combined therapy with thalidomide and narrow-band (TLO1) UVB in the treatment of prurigo nodularis | 9 | 12 |
| 518 | 0 | 0 | 1653 2003 BLOOD 102(11):691A-691A Feyler S; Jackson G; Rawstron A; El-Sherbiny YM; Snowden JA; Johnson RJ Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. | 0 | 1 |
| 519 | 6 | 28 | 706 1998 INTERNATIONAL JOURNAL OF STD & AIDS 9(12):751-755 Fife K; Howard MR; Gracie F; Phillips RH; Bower M Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre | 29 | 45 |
| 520 | 8 | 40 | 1269 2001 SEMINARS IN ONCOLOGY 28(4):62-66 Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | 16 | 38 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 521 | 4 | 17 | 1170 2001 CLINICAL CANCER RESEARCH 7(7):1888-1893 Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Kruger EA; Gubish E; Pluda JM; Reed E A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer | 25 | 60 |
| 522 | 0 | 0 | 959 2000 CLINICAL CANCER RESEARCH 6:4522S-4523S Figg WD; Dahut W; Libutti SK; Carrasquillo J; Bacharach S; Kurdziel K; Huebsch F; Kruger EA; Pluda J; Reed E Thalidomide, an angiogenesis inhibitor, has activity in metastatic prostate cancer. | 0 | 0 |
| 523 | 16 | 28 | 834 1999 JOURNAL OF PHARMACEUTICAL SCIENCES 88(1):121-125 Figg WD; Raje S; Bauer KS; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E Pharmacokinetics of thalidomide in an elderly prostate cancer population | 34 | 48 |
| 524 | 0 | 0 | 967 2000 DEVELOPMENTAL DYNAMICS 219(3):443-443 Fillmore BJ; Stephens TD Angiogenic integrin avb3 as a site of the teratogenic action of thalidomide | 0 | 0 |
| 525 | 6 | 34 | 1003 2000 JOURNAL OF CLINICAL ONCOLOGY 18(4):708-715 Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WKA Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | 78 | 150 |
| 526 | 4 | 37 | 1742 2003 JOURNAL OF CLINICAL ONCOLOGY 21(12):2299-2304 Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | 2 | 5 |
| 527 | 4 | 8 | 982 2000 GASTROENTEROLOGY 119(2):596-596 Fishman SJ; Feins NR; D'Amato RJ; Folkman J Thalidomide therapy for Crohn's disease | 5 | 12 |
| 528 | 8 | 20 | 880 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(2):171-174 Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L Thalidomide and thrombosis. | 25 | 27 |
| 529 | 1 | 2 | 53 1982 TERATOLOGY 25(2):A40-A40 FLINT OP THE EFFECT OF THALIDOMIDE ON MICROMASS CULTURES OF EMBRYONIC RAT-CELLS | 0 | 0 |
| 530 | 0 | 1 | 92 1983 NEW SCIENTIST 100(1378):49-49 FLOHE L THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 531 | 0 | 36 | 8 1981 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 31-1(2):315-320 FLOHE L; DRAEGER E; FRANKUS E; GRAUDUMS I; GUNZLER WA; HELM FC; KUUTTISAVOLAINEN ER STUDIES ON THE HYPOTHETICAL RELATIONSHIP OF THALIDOMIDE-INDUCED EMBRYOPATHY AND COLLAGEN BIOSYNTHESIS | 0 | 10 |
| 532 | 26 | 38 | 1790 2003 LEUKEMIA & LYMPHOMA 44(7):1141-1146 Flowers MED; Martin PJ Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease | 0 | 0 |
| 533 | 0 | 0 | 511 1996 BLOOD 88(10):2423-2423 Flowers MED; Tapscott SJ; Emerson J; Emerson MV; Reagan T; Taylor L; Ajer T; Siadak M; Sanders J; Zwingenberger K; Willsmann K; Appelbaum F; Sullivan KM Incidence of peripheral neuropathy (PN) prior to thalidomide treatment for chronic graft-versus-host disease (GVHD). | 0 | 0 |
| 534 | 10 | 13 | 513 1996 BONE MARROW TRANSPLANTATION 17(2):291-293 Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GAR Thalidomide responsive chronic pulmonary GVHD | 8 | 14 |
| 535 | 3 | 37 | 1055 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(1):35-47 Fort DJ; Stover EL; Bantle JA; Finch RA Evaluation of the developmental toxicity of thalidomide using Frog Embryo Teratogenesis Assay-Xenopus (FETAX): Biotransformation and detoxification | 6 | 8 |
| 536 | 7 | 12 | 1067 2001 AMERICAN JOURNAL OF HEMATOLOGY 66(4):300-302 Fowler R; Imrie K Thalidomide-associated hepatitis: A case report | 5 | 6 |
| 537 | 0 | 0 | 669 1998 ASM NEWS 64(10):557-558 Fox JL Thalidomide approved for treating leprosy | 1 | 1 |
| 538 | 6 | 6 | 1194 2001 GASTROENTEROLOGY 120(6):1567-1568 Fox MR; Harris A Intractable insomnia after cessation of treatment with thalidomide | 3 | 3 |
| 539 | 1 | 1 | 1195 2001 GASTROENTEROLOGY 121(3):747-747 Fox MR; Harris A Intractable insomnia after cessation of treatment with Thalidomide. (vol 120, pg 1567, 2001) | 0 | 0 |
| 540 | 5 | 25 | 1799 2003 MEDICAL ONCOLOGY 20(4):397-401 Fraiman G; Ganti AK; Potti A; Mehdi S Angiosarcoma of the small intestine - Possible role for thalidomide? | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 541 | 13 | 14 | 1443 2002 EUROPEAN JOURNAL OF DERMATOLOGY 12(1):63-65 Frances C; El Khoury S; Gompel A; Becherel PA; Chosidow O; Piette JC Transient secondary amenorrhea in women treated by thalidomide | 1 | 2 |
| 542 | 128 | 159 | 1943 2004 LANCET 363(9423):1802-1811 Franks ME; Macpherson GR; Figg WD Thalidomide | 0 | 0 |
| 543 | 0 | 2 | 42 1982 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 32-2(8):898-898 FRANKUS E; FRIDERICHS E; GRAUDUMS I; HELM FC CHEMICAL-STRUCTURE, TERATOGENICITY AND PHARMACOLOGICAL ACTIVITY OF THALIDOMIDE RELATED-COMPOUNDS | 0 | 1 |
| 544 | 0 | 0 | 243 1988 TERATOLOGY 38(3):201-202 FRASER FC THALIDOMIDE RETROSPECTIVE - WHAT DID WE LEARN | 1 | 4 |
| 545 | 0 | 0 | 736 1998 NEUROLOGY 50(4):A383-A384 Frennier JM; Abrey LE; Haimovitz-Friedman A; McLoughlin M; Rosenfeld MR Does thalidomide have a role in glioma angiogenesis? | 0 | 0 |
| 546 | 0 | 22 | 41 1982 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 32-1(6):613-620 FRIDERICHS E STUDIES ON THE CNS ACTIVITY PROFILE OF THALIDOMIDE ANALOGS | 0 | 8 |
| 547 | 0 | 0 | 1515 2002 JOURNAL OF THE NATIONAL CANCER INSTITUTE 94(17):1270-1272 Friedrich MJ Despite checkered past, thalidomide and its analogues show potential | 0 | 0 |
| 548 | 7 | 10 | 658 1998 AIDS PATIENT CARE AND STDS 12(12):903-906 Fu CS; Conteas CN; LaRiviere MJ Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus | 2 | 3 |
| 549 | 19 | 30 | 1474 2002 INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 6(7):569-572 Fu LM; Fu-Liu CS Thalidomide and tuberculosis | 2 | 3 |
| 550 | 5 | 5 | 1842 2004 ANNALS OF ONCOLOGY 15(3):537-537 Fuente N; Mane JM; Barcelo R; Munoz A; Perez-Hoyos T; Lopez-Vivanco G Tumor lysis syndrome in a multiple myeloma treated with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 551 | 12 | 27 | 1583 2003 ANTICANCER RESEARCH 23(3B):2405-2411 Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice | 0 | 0 |
| 552 | 12 | 56 | 1173 2001 CLINICAL CANCER RESEARCH 7(11):3349-3355 Fujita J; Mestre JR; Zeldis JB; Subbaramaiah K; Dannenberg AJ Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 | 22 | 32 |
| 553 | 8 | 24 | 1912 2004 HISTOCHEMISTRY AND CELL BIOLOGY 122(1):27-33 Fujita K; Asami Y; Tanaka K; Akita M; Merker HJ Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta | 0 | 0 |
| 554 | 0 | 0 | 308 1991 INTERNATIONAL JOURNAL OF STD & AIDS 2(5):369-370 FULLER GN; JACOBS JM; GUILOFF RJ THALIDOMIDE, PERIPHERAL NEUROPATHY AND AIDS | 5 | 7 |
| 555 | 8 | 11 | 1550 2002 REVUE DE MEDECINE INTERNE 23(8):724-727 Gachon J; Grob JJ; Richard MA Thalidomide treatment leading thrombotic events: two cases | 3 | 4 |
| 556 | 0 | 7 | 165 1985 LEPROSY REVIEW 56(1):35-39 GAD SM; SHANNON EJ; KROTOSKI WA; HASTINGS RC THALIDOMIDE INDUCES IMBALANCES IN LYMPHOCYTE-T SUB-POPULATIONS IN THE CIRCULATING BLOOD OF HEALTHY-MALES | 50 | 65 |
| 557 | 9 | 51 | 788 1999 CELLULAR AND MOLECULAR BIOLOGY 45(5):579-588 Gaffield W; Incardona JP; Kapur RP; Roelink H A looking glass perspective: Thalidomide and cyclopamine | 0 | 6 |
| 558 | 0 | 0 | 884 2000 ANNALS OF ONCOLOGY 11:96-96 Galani E; Grigoraki V; Kiamouris C; Samantas E; Economou O; Papdimitriou C; Gika D; Anagnostopoulos N; Dimopoulos M Thalidomide and dexamethasone combination for refractory multiple myeloma. | 0 | 0 |
| 559 | 6 | 10 | 1911 2004 HAEMATOLOGICA 89(9):1141-1142 Galli M; Elice F; Crippa E; Comotti B; Rodeghiero F; Barbui T Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma | 0 | 0 |
| 560 | 2 | 29 | 815 1999 INFLAMMATION 23(6):495-505 Gallily R; Kipper-Galperin M; Brenner T Mycoplasma fermentans-induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10 | 1 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 561 | 0 | 0 | 1131 2001 BLOOD 98(11):365B-365B Game M; Coso D; Sturgeon J; Crump M; Keating A Thalidomide and low dose vinblastine as palliative therapy for patients relapsing after autotransplant for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). | 0 | 1 |
| 562 | 0 | 4 | 1592 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(5):240-240 Garcia BD; Gafas AD; Alvarez MJF Lung toxicity due to thalidomide | 0 | 0 |
| 563 | 27 | 54 | 1946 2004 LEUKEMIA 18(4):856-863 Garcia-Sanz R; Gonzalez-Porras JR; Hernandez JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; Lopez R; Grande-Garcia C; Alegre A; Vargas-Pabon M; Gutierrez ON; Rodriguez JA; San Miguel JF The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma | 0 | 1 |
| 564 | 6 | 10 | 368 1993 MEDICINA CLINICA 100(14):557-557 GARCIAALBEA E; CABRERA F; TEJEIRO J; JIMENEZJIMENEZ FJ MIGRAINE AND THALIDOMIDE | 0 | 0 |
| 565 | 0 | 4 | 168 1985 PEDIATRIC RESEARCH 19(4):A324-A324 GARDNER LI; WELSHSLOAN J; CADY RB PHOCOMELIA OF LEFT LOWER LEG IN AN INFANT WHOSE MOTHER TOOK LARGE DOSES OF PYRIDOXINE (B-6) - DEJA VU OF THE THALIDOMIDE DISASTER | 0 | 0 |
| 566 | 15 | 43 | 422 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):860-862 GARDNERMEDWIN JM; POWELL RJ THALIDOMIDE - THE WAY FORWARD | 7 | 10 |
| 567 | 7 | 22 | 380 1994 ANNALS OF THE RHEUMATIC DISEASES 53(12):828-832 GARDNERMEDWIN JMM; SMITH NJ; POWELL RJ CLINICAL-EXPERIENCE WITH THALIDOMIDE IN THE MANAGEMENT OF SEVERE ORAL AND GENITAL ULCERATION IN CONDITIONS SUCH AS BEHCETS-DISEASE - USE OF NEUROPHYSIOLOGICAL STUDIES TO DETECT THALIDOMIDE NEUROPATHY | 53 | 73 |
| 568 | 1 | 33 | 183 1986 CURRENT CONTENTS (50):3-11 GARFIELD E TERATOLOGY LITERATURE AND THE THALIDOMIDE CONTROVERSY | 0 | 0 |
| 569 | 6 | 8 | 1498 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):987-988 Gaspari A Thalidomide neurotoxicity in dermatological patients: The next "STEP'' | 1 | 2 |
| 570 | 0 | 0 | 883 2000 ANNALS OF ONCOLOGY 11:60-60 Gasparini G; Gilberti S; Vitale S; Arena MG; Fanelli M; Ranieri G; Gattuso D; Biondi E; Morabito A Antitumoral activity of Thalidomide in patients affected by refractory breast cancer nad recurrent high grade gliomas. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 571 | 0 | 0 | 1851 2004 BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS 1657:55-56 Gattermann N Sequential dHPLC analysis of a clonally expanded mitochondrial tRNALeu(UUR) mutation (G3242A) in a patient with myelodysplastic syndrome (preleukemia) during successful treatment with thalidomide | 0 | 0 |
| 572 | 2 | 31 | 458 1995 FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 12(3-4):165-174 GEIST C; WOHRMANN T; SCHNEIDER J; ZWINGENBERGER K EFFECTS OF THALIDOMIDE ON THE LOCAL SHWARTZMAN REACTION IN MICE AND RABBITS | 6 | 8 |
| 573 | 9 | 28 | 531 1996 IMMUNOPHARMACOLOGY 31(2-3):213-221 Geitz H; Handt S; Zwingenberger K Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade | 75 | 94 |
| 574 | 10 | 26 | 1756 2003 JOURNAL OF NEURO-ONCOLOGY 64(3):193-201 Gelati M; Corsini E; Frigerio S; Pollo B; Broggi G; Croci D; Silvani A; Boiardi A; Salmaggi A Effects of thalidomide on parameters involved in angiogenesis: an in vitro study | 0 | 1 |
| 575 | 2 | 17 | 114 1984 DERMATOLOGICA 168(4):182-188 GENVO MF; FAURE M; THIVOLET J THALIDOMIDE AND THALIDOMIDE WITH COLCHICINE IN THE TREATMENT OF APHTHOSIS, RECURRENT MUCOCUTANEOUS APHTHAE AND BEHCETS-DISEASE | 8 | 16 |
| 576 | 7 | 10 | 690 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(3):141-141 Georgala S; Katoulis AC; Hasapi V; Koumantaki-Mathioudaki E Thalidomide treatment for hypertrophic lupus erythematosus | 3 | 3 |
| 577 | 8 | 38 | 1043 2000 PAIN 88(3):267-275 George A; Marziniak M; Schafers M; Toyka KV; Sommer C Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin | 4 | 21 |
| 578 | 6 | 6 | 1236 2001 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 45(6):965-966 George SJ; Hsu S Lichen planopilaris treated with thalidomide | 3 | 6 |
| 579 | 4 | 10 | 325 1992 JOURNAL OF INFECTIOUS DISEASES 166(4):939-940 GEORGHIOU PR; ALLWORTH AM THALIDOMIDE IN PAINFUL AIDS-ASSOCIATED PROCTITIS | 11 | 21 |
| 580 | 2 | 4 | 289 1990 MEDICAL JOURNAL OF AUSTRALIA 152(7):382-383 GEORGHIOU PR; KEMP RJ HIV-ASSOCIATED ESOPHAGEAL ULCERS TREATED WITH THALIDOMIDE | 6 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 581 | 7 | 23 | 306 1991 CANCER LETTERS 60(2):129-133 GERSHBEIN LL THE THALIDOMIDE ANALOG, EM-12, ENHANCES 1,2-DIMETHYLHYDRAZINE-INDUCTION OF RAT COLON ADENOCARCINOMAS | 2 | 6 |
| 582 | 0 | 0 | 481 1995 NATURE MEDICINE 1(12):1230-1230 GERSHON D FINDING NEW USES FOR THALIDOMIDE | 3 | 5 |
| 583 | 3 | 6 | 367 1993 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 28(2):271-272 GHIGLIOTTI G; REPETTO T; FARRIS A; ROY MT; DEMARCHI R THALIDOMIDE - TREATMENT OF CHOICE FOR APHTHOUS ULCERS IN PATIENTS SEROPOSITIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS | 31 | 39 |
| 584 | 11 | 28 | 1668 2003 BONE MARROW TRANSPLANTATION 32(6):587-592 Ghobrial IM; Dispenzieri A; Bundy KL; Gastineau DA; Rajkumar SV; Therneau TM; Lacy MQ; Witzig TE; Litzow MR; Christensen BR; Hayman S; Pribula CG; Gertz MA Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma | 1 | 1 |
| 585 | 0 | 0 | 1379 2002 BLOOD 100(11):434A-434A Ghobrial IM; Kumar S; Porrata LF; Gertz MA; Gastineau DA; Ansell SM; Lacy MQ; Rajkumar VS; Micallef IN; Tefferi A; Dispenzieri A; Inwards D; Litzow MR; Markovic SN Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in Multiple Myeloma. | 0 | 0 |
| 586 | 14 | 24 | 1585 2003 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 47(8):2445-2449 Giamarellos-Bourboulis EJ; Poulaki H; Kostomitsopoulos N; Dontas I; Perrea D; Karayannacos PE; Giamarellou H Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide | 0 | 1 |
| 587 | 3 | 7 | 1802 2003 NEUROLOGY 60(5):877-878 Giannini F; Volpi N; Rossi S; Passero S; Fimiani M; Cerase A Thalidomide-induced neuropathy: a ganglionopathy? | 3 | 3 |
| 588 | 0 | 0 | 913 2000 BLOOD 96(11):288B-288B Gibson RK; Alley L; Shuman HW Thalidomide (Thal) monotherapy is effective in previously treated recurrent multiple myeloma (MM). | 0 | 0 |
| 589 | 58 | 116 | 1072 2001 ANNALS OF MEDICINE 33(8):516-525 Ginsburg PM; Dassopoulos T; Ehrenpreis ED Thalidomide treatment for refractory Crohn's disease: a review. of the history, pharmacological mechanisms and clinical literature | 9 | 13 |
| 590 | 8 | 26 | 1284 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(12):2115-2122 Ginsburg PM; Ehrenpreis ED A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 591 | 4 | 7 | 1065 2001 AMERICAN JOURNAL OF GASTROENTEROLOGY 96(4):1305-1306 Ginsburg PM; Hanan I; Ehrenpreis ED Treatment of severe esophageal Crohn's disease with thalidomide | 8 | 10 |
| 592 | 11 | 20 | 1524 2002 LEUKEMIA & LYMPHOMA 43(12):2301-2307 Giovanni B; Michelle E; Letizia C; Filippo B; Paolo PP; Giuseppe V; Monia M; Gabriele P; Francesca Z; Ayalew T Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies | 0 | 0 |
| 593 | 0 | 4 | 203 1987 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 114(11):1387-1389 GNASSIA AM; GNASSIA RT; BONVALET D; PUISSANT A; GOUDAL H HISTIOCYTOSIS-X WITH VULVAR LOCALIZATION - DRAMATIC EFFECT OF THALIDOMIDE | 15 | 23 |
| 594 | 1 | 9 | 1426 2002 CLINICAL CANCER RESEARCH 8(8):2750-2750 Go RS; Horstman AL Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. | 0 | 0 |
| 595 | 24 | 42 | 1925 2004 JOURNAL OF IMMUNOLOGY 172(8):5103-5109 Gockel HR; Lugering A; Heidemann J; Schmidt M; Domschke W; Kucharzik T; Lugering N Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway | 0 | 0 |
| 596 | 9 | 33 | 1577 2003 ANNALS OF HEMATOLOGY 82(10):654-659 Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IGD; Martin H; Hoelzer D; Ho AD; Lokhorst HM Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients | 0 | 0 |
| 597 | 0 | 2 | 213 1987 PRENATAL DIAGNOSIS 7(4):295-298 GOLLOP TR; EIGIER A PRENATAL-DIAGNOSIS OF THALIDOMIDE SYNDROME | 5 | 6 |
| 598 | 1 | 5 | 1567 2003 AMERICAN JOURNAL OF HEMATOLOGY 74(4):290-291 Gomez-Rangel JD; Ruiz-Delgadoz GJ; Ruiz-Arguelles GJ Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myelorna receiving thalidomide | 0 | 0 |
| 599 | 0 | 0 | 759 1999 ARTHRITIS AND RHEUMATISM 42(10):2259-2260 Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al | 8 | 9 |
| 600 | 6 | 7 | 1406 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(3):883-884 Gonzalez-Porras JR; Gonzalez M; Garcia-Sanz R; San Miguel JF Thalidomide in combination with cyclophosphamide and dexamethasone (ThaCyDex) is effective in soft-tissue plasmacytomas | 0 | 0 |